Brain Protein Arc May Be the Hidden Culprit Behind Alzheimer's Spread

A Surprising Accomplice in Alzheimer's Progression

For decades, researchers have known that a toxic protein called Tau plays a central role in Alzheimer's disease. What they didn't fully understand was how that protein manages to migrate through the brain, corrupting healthy cells along the way. Now, a new study has identified an unexpected accomplice — a widely studied brain protein called Arc — and the discovery could reshape the future of Alzheimer's treatment.

The findings, published in the prestigious journal Cell, suggest that rather than trying to eliminate Tau entirely, future therapies might focus on intercepting it before it reaches healthy neurons.

What Is Tau — and Why Does It Matter?

Tau is a protein found in every neuron in the brain. Under normal circumstances, it plays a supportive structural role. But in Alzheimer's disease, Tau begins to misfold and clump together into dense, sticky tangles that clog the cell's internal transport system and ultimately destroy the neuron.

Mitali Tyagi, PhD, a postdoctoral research associate at Washington University in St. Louis and the study's first author, describes these tangles vividly: "They glue together and block transportation within the neuron. But they can break down into smaller glue monsters, called Tau seeds, which can then get transferred to a new neuron. And once this Tau seed comes into contact with healthy Tau, it is able to corrupt it. So, the pathology starts all over again in a healthy neuron."

This cell-to-cell spread is what drives Alzheimer's relentless progression, causing worsening memory loss and cognitive decline over time.

The Role of the Arc Protein

Under normal conditions, Arc is a beneficial player in brain function. It packages itself inside tiny, membrane-enclosed structures called extracellular vesicles (EVs) — essentially microscopic delivery pods that neurons use to send chemical signals to one another.

However, researchers at the University of Utah Health discovered that toxic Tau can hijack this natural communication system. By latching onto Arc inside these vesicles, Tau is able to hitch a ride from a diseased neuron into a perfectly healthy one, seeding new damage wherever it lands.

To confirm Arc's role, the research team compared Alzheimer's mouse models that had Arc with those that did not. The results were striking.

"When we removed Arc, we saw that the transfer of Tau was severely, severely reduced," Tyagi says. "It was almost gone."

In mice without Arc, extracellular vesicles contained very little Tau, and the protein's ability to spread to neighboring brain cells was dramatically curtailed.

A Double-Edged Sword

Despite these findings, simply blocking Arc altogether may not be the right therapeutic approach. The researchers found that Arc also serves a protective function — particularly in the early stages of the disease.

When a neuron becomes overwhelmed with toxic Tau, Arc helps expel that excess protein by packaging it into extracellular vesicles. This process allows the damaged cell to survive longer. Without Arc, toxic Tau builds up inside sick neurons at an accelerated rate, causing them to die more quickly.

"When Arc is absent, Tau becomes trapped inside neurons and accumulates to toxic levels. When Arc is present, Tau can be released in extracellular vesicles. While this helps reduce Tau buildup within the original neuron, the released Tau can be taken up by neighboring healthy neurons, promoting the spread of pathology," Tyagi explains.

In other words, Arc is simultaneously helping diseased cells survive and inadvertently spreading the disease to healthy ones.

A New Direction for Treatment

This nuanced understanding points researchers toward a more precise therapeutic strategy: rather than shutting down Arc entirely — which could accelerate neuron death — the goal should be to intercept Tau-laden extracellular vesicles after they leave diseased cells but before they enter healthy ones.

"If we could target these particular EVs, that would be a really useful therapy strategy," says Jason Shepherd, PhD, professor of neurobiology at the University of Utah Health and senior author of the study. "For someone with early-onset Alzheimer's or dementia, if we could stop the spread, then we could prevent further damage and cognitive decline."

Such a treatment would not reverse existing brain damage, but it could potentially halt — or at least significantly slow — the disease's progression.

From Mice to Humans: A Cautious Path Forward

Adding weight to the research, the team also detected extracellular vesicles containing both Arc and Tau in human brain tissue, suggesting this same mechanism may operate in people with Alzheimer's, not just in animal models.

However, the researchers are careful to temper expectations. "Most of the work we've been doing is in mice, not in humans," Shepherd notes. "We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet. And we're far away from saying that we're developing a treatment for anything. But it could open new avenues to get to that point."

Why This Discovery Matters

Alzheimer's disease affects tens of millions of people worldwide, and current treatments remain limited in their ability to slow the disease's course. Identifying a new mechanism by which Alzheimer's spreads — and a potential way to block it — represents a meaningful step forward.

"I'm excited by the fact that we've identified a new way of potentially stopping the progression of Alzheimer's disease," says Shepherd.

The study, titled "Arc mediates intercellular tau transmission via extracellular vesicles," was supported by the National Institutes of Health, the Alzheimer's Association, the Chan-Zuckerberg Initiative, the Rainwater Foundation, the JPB Foundation, and the Cure Alzheimer Fund, among others.